Leucovorin calcium
Leucovorin (leucovorin calcium) is a small molecule pharmaceutical. Leucovorin calcium was first approved as Leucovorin calcium on 1982-01-01. It is used to treat folic acid deficiency and megaloblastic anemia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enbrace hr | unapproved drug other | 2025-12-17 |
| enlyte | unapproved drug other | 2022-07-01 |
| lederle leucovorin | unapproved drug for use in drug shortage | 2025-12-18 |
| leucovorin | ANDA | 2014-09-26 |
| leucovorin calcium | ANDA | 2025-12-09 |
| paxlyte | unapproved drug other | 2025-12-08 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0640 | Injection, leucovorin calcium, per 50 mg |
Clinical
Clinical Trials
2712 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 122 | 345 | 175 | 9 | 25 | 613 |
| Neoplasms | D009369 | — | C80 | 124 | 95 | 32 | 2 | 10 | 234 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 77 | 137 | 40 | 1 | 12 | 230 |
| Rectal neoplasms | D012004 | — | — | 46 | 114 | 51 | 1 | 10 | 207 |
| Colonic neoplasms | D003110 | — | C18 | 46 | 86 | 60 | 1 | 13 | 186 |
| Adenocarcinoma | D000230 | — | — | 32 | 102 | 30 | 1 | 6 | 155 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 30 | 102 | 27 | 2 | 8 | 152 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 31 | 67 | 26 | 1 | 4 | 121 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 2 | 4 | 10 | 8 | 56 | 79 |
| Lymphoma | D008223 | — | C85.9 | 16 | 43 | 15 | 1 | 7 | 73 |
Show 113 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 16 | 40 | 26 | — | 5 | 79 |
| Carcinoma | D002277 | — | C80.0 | 13 | 36 | 16 | — | 5 | 62 |
| Leukemia | D007938 | — | C95 | 8 | 35 | 19 | — | 4 | 61 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 7 | 32 | 18 | — | 5 | 56 |
| Pancreatic ductal carcinoma | D021441 | — | — | 23 | 26 | 6 | — | 1 | 49 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 8 | 29 | 5 | — | 1 | 34 |
| Recurrence | D012008 | — | — | 16 | 16 | 3 | — | 2 | 32 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 16 | 17 | 6 | — | 3 | 32 |
| Fallopian tube neoplasms | D005185 | — | — | 16 | 15 | 8 | — | — | 32 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 11 | 14 | 7 | — | 2 | 30 |
Show 199 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | 2 | — | — | 16 | 27 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 12 | 11 | — | — | — | 16 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 13 | 4 | — | — | — | 15 |
| Triple negative breast neoplasms | D064726 | — | — | 12 | 8 | — | — | — | 15 |
| Osteosarcoma | D012516 | — | — | 7 | 6 | — | — | 3 | 15 |
| Sarcoma | D012509 | — | — | 6 | 7 | — | — | 1 | 14 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | 3 | — | — | 10 | 14 |
| Myelodysplastic syndromes | D009190 | — | D46 | 8 | 4 | — | — | — | 11 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 2 | — | — | 9 | 11 |
| Hodgkin disease | D006689 | — | C81 | 7 | 5 | — | — | — | 10 |
Show 164 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 5 | — | — | — | 1 | 6 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 5 | — | — | — | — | 5 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 3 | — | — | — | 2 | 5 |
| Sezary syndrome | D012751 | — | C84.1 | 3 | — | — | — | 1 | 4 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | — | 1 | 3 |
| Chondrosarcoma | D002813 | — | — | 2 | — | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | 1 | 2 |
| Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | 1 | — | — | — | 1 | 2 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
Show 54 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gyrate atrophy | D015799 | — | — | — | — | — | — | 12 | 12 |
| Breast feeding | D001942 | — | — | — | — | — | — | 8 | 8 |
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | — | — | — | 7 | 7 |
| Alopecia | D000505 | — | L64 | — | — | — | — | 5 | 5 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 5 | 5 |
| Feeding behavior | D005247 | — | — | — | — | — | — | 5 | 5 |
| Diet therapy | D004035 | — | — | — | — | — | — | 4 | 4 |
| Child development | D002657 | — | — | — | — | — | — | 4 | 4 |
| Nutritional status | D009752 | — | — | — | — | — | — | 4 | 4 |
| Postoperative cognitive complications | D000079690 | — | — | — | — | — | — | 4 | 4 |
Show 203 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Leucovorin calcium |
| INN | calcium folinate |
| Description | Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2] |
Identifiers
| PDB | — |
| CAS-ID | 1492-18-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201138 |
| ChEBI ID | — |
| PubChem CID | 6006 |
| DrugBank | DB00650 |
| UNII ID | RPR1R4C0P4 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,652 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enlyte
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,341 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use